STAT+: Pharmalittle: Senate bill would allow insulin makers to lock in profits; GSK, Novartis pledge funds for diseases that mostly affect the poor
Rise and shine, everyone, another busy day is on the way. We can tell because Mrs. Pharmalot and the official mascot have long since departed for their morning constitutional, another food delivery is imminent, and our to-do list has already grown. This calls, as you may imagine, for a cup or three of stimulation. Our choice today is pumpkin spice, which has been hiding in the back of our pantry. Meanwhile, here is the latest laundry list of interesting items to help you on your journey today. We hope all goes well and you conquer the world. But while you do, please remember to keep in touch. We appreciate juicy tips…
A new proposal that senators claim would fix insulin pricing would actually allow drugmakers to lock in their current profits from the medicine for the foreseeable future, STAT explains. The bill, introduced Wednesday by Sens. Jeanne Shaheen (D-N.H.) and Susan Collins (R-Maine), proposes a complicated redesign of how insulin products are priced, and what patients pay for them. The proposal could help a minority of patients who use insulin, and Senate leadership is hoping to speed it to a vote this summer. But the fix would likely spread costs to all Medicare patients, insurers, and the federal government, without actually changing how much drug makers make on the medicine.
Continue to STAT+ to read the full story…
